Instem, a Conshohocken, Pennsylvania, provider of IT solutions to the global life sciences market, has acquired Columbus-based Leadscope Inc. as part of its mission to further consolidate and harmonize key application areas that are helping customers streamline and accelerate their R&D processes.

Founded in 1997, Leadscope is a leader in computational toxicology. Its clients include pharmaceutical, chemical and consumer products organizations, as well as international regulatory agencies. Leadscope’s solutions allow researchers to combine their proprietary data with publicly-curated toxicity databases. Clients searching Leadscope’s toxicity databases can access more than 500,000 toxicology studies for over 200,000 chemicals, enabling fast, accurate, defendable and regulatory accepted predictions.

Leadscope CEO Dr. Glenn Myatt said, in a statement, “The Instem brand is synonymous with innovation and market leadership, and they have managed to balance their growth while maintaining excellent service to their clients – something that is highly important for us here at Leadscope.”

The Leadscope team will be part of Instem’s scientific division.

“This acquisition is a great fit for us, and the synergies created will further help us enable clients to make better informed decisions,” Instem CEO Phil Reason said, in a statement. “We have been in regular dialogue with Glenn and the Leadscope team for over 10 years, and with the increasing needs of the market for in silico tools, both in regulatory submissions and in safety profile screening, the timing is perfect. They have built a deep relationship with the regulatory authorities, a fantastic client base and have an excellent reputation in the market as true collaborators.”

Instem supports its global roster of more than 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.